| Patient | Jesse Owens |
|---|---|
| Date of birth | 1960-09-12 |
| Identifiers | MRN HR-ML042-SYN; SSN (made up) 000-42-8319 |
| Document date | 2026-08-05 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after three cycles: restaging CT and the decision for surgery. [S]
Mr. Owens returns three weeks after his third cycle. The cold he had at the sick visit cleared in a week, and the third cycle went ahead on schedule. Restaging CT five days ago shows the nodule shrunk from 2.9 to 1.3 cm and the interlobar node from 1.6 to 0.8 cm, with nothing new. The thoracic surgeon has booked a thoracoscopic left upper lobectomy in two weeks. He finished 16 prehabilitation sessions and walks 3 km again. He has not smoked for nine weeks. He feels a little more tired than usual, without cold intolerance, weight gain or constipation. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Restaging CT | Partial response: primary 1.3 cm (from 2.9), node 0.8 cm (from 1.6); no new disease |
| Planned operation | Thoracoscopic left upper lobectomy with lymph node dissection in two weeks |
| Tobacco | Abstinent nine weeks |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly more tired than usual; weight 75.2 kg; no fever |
| Respiratory | Negative | Cough gone since the cold cleared; no breathlessness |
| Endocrine | Negative | No cold intolerance, weight gain or constipation |
| Gastrointestinal | Negative | No diarrhea or nausea |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood good; PHQ-2 1 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 2026-05-26 to 2026-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 2026-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 2026-06-03 to 2026-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 2026-05-26 to 2026-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 2026-05-26 to 2026-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 2026-06-02 to 2026-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 2026-06-03 to 2026-07-31 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-05 | Body height | 178 | cm | S |
| 2026-08-05 | Body weight | 75.2 | kg | S |
| 2026-08-05 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 2026-08-05 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-05 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-05 | Heart rate | 72 | /min | S |
| 2026-08-05 | Respiratory rate | 14 | /min | S |
| 2026-08-05 | Body temperature | 36.5 | Cel | S |
| 2026-08-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-05 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.5-17.5 g/dL | Low | S |
| 2026-08-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-05 | Neutrophils [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-08-05 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-05 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-08-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-05 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-05 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-08-05 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-08-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-48 U/L | Normal | S |
| 2026-08-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 40-129 U/L | Normal | S |
| 2026-08-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-08-05 | Thyrotropin [Units/volume] in Serum or Plasma | 6.8 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 2026-08-05 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-08-05 | Cortisol [Mass/volume] in Serum or Plasma | 12.9 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 2026-08-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2026-08-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 75.2 kg; blood pressure 124/76, pulse 72; oxygen saturation 97 percent |
| Neck | Thyroid not enlarged or tender |
| Respiratory | Clear throughout |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Reflexes normal; no tremor |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | active | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
| Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Response imaging | After the three cycles before surgery | Completed today | CT five days ago: partial response, no new disease |
| Laboratory | Blood count with neutrophils and platelets | Before surgery | Completed today | Hemoglobin 12.8 (low), white cells 6.2, neutrophils 3.6, platelets 188 |
| Laboratory | Chemistry before surgery: sodium, potassium, calcium, albumin, alkaline phosphatase | Before surgery | Completed today | Sodium 138, potassium 4.3, calcium 9.3, albumin 4.0, alkaline phosphatase 90 |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Before each infusion and after the last dose | Completed today | TSH 6.8 (high) with free T4 1.0: subclinical thyroiditis, grade 1; ALT 31, AST 27, bilirubin 0.6; creatinine 1.1, eGFR 74; glucose 95 |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Completed today | 12.9 mcg/dL at 8 a.m., normal; drawn today as the corrective action for the gap recorded at cycle 2, which closes that deviation with no harm found |
| Imaging | Repeat pulmonary function before surgery | If symptoms or a clinical change after chemotherapy | Not indicated | No new breathlessness, and the values ten weeks ago were well above the thresholds; the surgeon agreed |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent nine weeks |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 1 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | No cough or breathlessness |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | None |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before lung resection | Completed today | Program of 16 sessions completed |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013); Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S (PMID 23649443) (2013); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021)
Follow-up: Lobectomy in two weeks. Visit six weeks after surgery with thyroid tests and the pathology. Call for fever, breathlessness or wound problems after the operation. Next scheduled visit 2026-09-30: six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation. [S]